Search

Your search keyword '"Wieske, Luuk"' showing total 380 results

Search Constraints

Start Over You searched for: Author "Wieske, Luuk" Remove constraint Author: "Wieske, Luuk"
380 results on '"Wieske, Luuk"'

Search Results

1. Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy

2. Immune responses to SARS-CoV-2 in sub-Saharan Africa and western Europe: a retrospective, population-based, cross-sectional study

3. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

4. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

6. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

8. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

11. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

12. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

13. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

15. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

16. Consumptive coagulopathy is associated with a disturbed host response in patients with sepsis

17. Patient‐reported daily functioning after SARS‐CoV‐2 vaccinations in autoimmune neuromuscular diseases.

18. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

19. Inflammatory Neuropathy Consortium base (INCbase):a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy

20. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

21. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

22. Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives

23. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

24. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

25. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

26. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

28. Suppressed IgG4 class switching in dupilumab‐ and TNF inhibitor‐treated patients after mRNA vaccination.

29. Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy.

31. Serum Contactin-1 in CIDP: A Cross-Sectional Study

32. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

34. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort

35. Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination

36. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study

39. Peripherin is a biomarker of axonal damage in peripheral nervous system disease

41. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study

42. B-cell targeting with anti-CD38 daratumumab:implications for differentiation and memory responses

43. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

44. SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

45. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases:long-term humoral immune responses and effects on disease activity

46. Gut barrier dysfunction and the risk of ICU-acquired bacteremia- a case–control study.

47. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

48. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort.

49. Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons

Catalog

Books, media, physical & digital resources